Recent studies have revealed elevated expression of transforming growth factor b1 (TGF-b1) in gastric mucosa of patients with gastric cancer (GC) and those undergoing ulcer repair. As production of TGF-b1 is genetically regulated, we aimed to assess whether functional polymorphisms of the TGFB1 gene are involved in susceptibility to and clinical characteristics of Helicobacter pylori-related diseases. DNA from 142 unrelated Spanish patients with GC, 200 with peptic ulcer and 342 healthy controls was typed for the MspA1I T þ 869C, and the Sau96I G þ 915C polymorphisms of the TGFB1 gene using polymerase chain reaction and RFLP analysis. H. pylori infection and CagA/VacA antibody status were determined by Western blot in patients and controls. H. pylori infection (odds ratio (OR): 11.44; 95% confidence interval (CI): 4.45-29.42; Po0.001) and nonsteroidal anti-inflammatory drugs (OR: 5.07; 95% CI: 2.53-10.16; Po0.001) were identified as independent risks factors for duodenal ulcer (DU), whereas the TGFB1 þ 869*C/C genotype was associated with reduced risk of developing the disease (OR: 0.32; 95% CI ¼ 0.15-0.68; P ¼ 0.003). Our results show that the TGFB1 T þ 869C gene polymorphism is involved in the susceptibility to DU and provide further evidence that host genetic factors play a key role in the pathogenesis of H. pylorirelated diseases.
Introduction
The clinical outcome of Helicobacter pylori (H. pylori) infection is most likely the result of complex interactions among bacteria, their hosts and environmental factors. H. pylori causes chronic inflammation of the gastric mucosa in virtually all infected individuals, but only a minority develop clinically relevant disease that includes peptic ulcer (PU), gastric carcinoma or gastric mucosa-associated lymphoid tissue lymphoma. 1 Some bacterial virulence determinants, such as the vacuolating cytotoxin VacA and the presence of the CagA pathogenicity island (cag PAI), have been associated with enhanced epithelial cell injury and a higher degree of gastric mucosal inflammation in patients with PU and gastric cancer (GC). [2] [3] [4] However, these findings have not been confirmed in all studies, and not all patients infected with CagA þ or VacAs1 þ strains develop clinically significant pathologies throughout life. [5] [6] [7] Moreover, clinical and epidemiological studies have reported an inverse association between duodenal ulcer (DU) disease and GC. 8, 9 Taking into account that close to 100% of patients with DU are infected with H. pylori, it seems likely that some processes in patients with DU might modify the risk of GC associated with H. pylori infection.
Besides environmental factors, the genetic background of an individual might play an important role in the outcome of H. pylori infection by controlling the nature and intensity of the inflammatory response to the bacteria into the gastric mucosa. Among the wide variety of pro-and anti-inflammatory mediators upregulated in the H. pylori-infected gastric mucosa, transforming growth factor b (TGF-b) and the TGF-b signalling pathway have been suggested as key players in the pathogenesis of H. pylori-associated diseases. Enhanced expression of the most predominat isoform TGF-b1 has been documented in gastric mucosa of patients with GC as well as in mucosa undergoing ulcer repair. 10, 11 Shih et al. 12 found that TGF-b and its receptors were increased in the gastric mucosa of patients with well-healed gastric ulcers (GU), whereas their expression was lower or absent in those patients with ulcers refractory to standard treatment. 12 In addition, recent studies showed that exogenous administration of TGF-b accelerates healing of experimental gastrointestinal ulcers. 13, 14 With regard to GC, overexpression of both the type II TGF-b1 receptor and TGF-b1 itself has been associated with progression and invasiveness of the tumour. 15 Moreover, conditional loss of TGF-b activity in gastric mucosa of mice has been associated with increased susceptibility to gastrointestinal carcinogenesis. 16 For most normal cell types, TGF-b1 acts as a potent inhibitor of proliferation and migration. However, in cells in which these suppressor functions are overridden, TGF-b1 may induce cellular changes associated with tumour development and progression. 17 Given the relevance of TGF-b and its signalling pathway in the pathogenesis of H. pylori-related diseases, it is possible that certain DNA sequence variants of the TGFB1 gene that contribute to differential expression of this mediator might increase the risk of developing PU and GC. Two single-nucleotide polymorphisms (SNPs) at positions þ 869 (T-C) and þ 915 (G-C) in the signal protein sequence, which change codon 10 (Leu-Pro) and codon 25 (Arg-Pro), respectively, have been related to variations in the production of TGF-b1, both in vitro and at the serum level. 18, 19 The correlation between these polymorphisms and disease status has been studied in a diverse range of diseases, [20] [21] [22] [23] but no studies have been published that examine the possible link between TGFB1 gene polymorphisms and H. pylori-related diseases. Therefore, the aim of our study was to assess whether the TGFB1 T þ 869C and TGFB1 G þ 915C polymorphisms are involved in susceptibility to and clinical characteristics of PU and GC.
Results

Clinical and demographic characteristics of patients and controls
The clinical and demographic characteristics of PU patients, GC patients and their gender-and age-matched healthy controls are shown in Table 1 . Among the evaluated features, H. pylori infection was significantly associated with a higher risk of developing DU or GU (odds ratio (OR): 9.29; 95% confidence interval (CI): 3.97-21.75; Po0.0001, and OR: 2.14; 95% CI: 1.04-4.38; P ¼ 0.04, respectively). On the other hand, infection with CagA þ strains was significantly more frequent in GC patients than in controls (67 vs 48.2%; OR: 2.18; 95% CI: 1.37-3.5; P ¼ 0.001). No differences in the prevalence of VacA þ strains between GC patients, PU patients and controls were observed. Finally, non-steroidal antiinflammatory drugs' (NSAIDs) use was also found to be a risk factor for the development of DU and GU (OR: 3.8; 95% CI: 2.4-6; Po0.0001, and OR: 13.22; 95% CI: 7.1-24.6; Po0.0001, respectively).
TGFB1 codons 10 and 25 polymorphisms Single marker analysis. Genotypes and allele frequencies of the TGFB1 T þ 869C (Leu-Pro) and TGFB1 G þ 915C (Arg-Pro) gene polymorphisms in patients and controls are shown in Table 2 . Genotype frequencies of these polymorphisms did not deviate significantly from Hardy-Weinberg expectation in the control group (chisquare (w
. No significant differences were observed in carriage rate, genotype or allele frequencies of the TGFB1 G þ 915C gene polymorphism between DU, GU, GC patients, and controls. In addition, no differences were found when patients were stratified according to gender, age of onset, smoking habit, family history of PU or GC, site of the ulcer, localization of the tumour or histological type (data not shown).
Concerning the TGFB1 T þ 869C (Leu/Pro) gene polymorphism, a strong association between the TGFB1 þ 869C/C genotype and decreased risk of DU was observed. In the DU group, the frequency of the TGFB1 þ 869C/C genotype was significantly lower than in healthy controls (10.1 vs 20.7%; OR: 0.26; 95% CI: 0.12-0.56; P ¼ 0.0006). This association was unrelated to NSAIDs use and still remained highly significant in the group of DU patients who had not taken NSAIDs (n ¼ 85; OR: 0.24, 95% CI: 0.09-0.59; P ¼ 0.001). Interestingly, no associations between this polymorphism and GU or GC TGFB1 polymorphisms and H. pylori-related diseases MA Garcia-Gonzalez et al were found. With regard to the latter, no differences in carriage rate, genotype or allele frequencies of the TGFB1 T þ 869C (Leu/Pro) gene polymorphism were found when GC patients were stratified according to tumour site or histological subtype. However, significant differences in TGFB1 T þ 869C genotype distribution were found within the different group of patients. Specifically, homozygosity for the TGFB1 þ 869*C allele (Pro/Pro) was significantly higher in patients with non-cardia GC compared to those with DU (26.3 vs 10.1%; OR: 2.81; 95% CI: 1.32-5.96; P ¼ 0.01).
TGFB1 haplotype analysis. We have previously reported that alleles of the two TGFB1 T þ 869C and TGFB1 G þ 915C gene polymorphisms are arranged in three restricted combinations denoted as TGFB1 haplotype 1
. 21 Both the TGFB1 þ 869 and TGFB1 þ 915 loci were in strong linkage disequilibrium in our data set
. The TGFB1 haplotype data in patients and controls are summarized in Table 3 . Similar to the independent analysis for each polymorphism, individuals homozygous for the TGFB1 haplotype 2 were significantly less prevalent in the group of DU patients than in the healthy control group (7.2 vs 14.6%; OR: 0.26; 95% CI: 0.11-0.61; P ¼ 0.002). However, no associations between TGFB1 haplotypes and GU or GC were found. 
Discussion
We have evaluated in this study the relevance of the TGFB1 T þ 869C and the TGFB1 G þ 915C polymorphisms in the susceptibility to PU and GC, two different pathologies related with H. pylori infection in which an abnormal expression of TGF-b1 has been documented. 10, 11, 24 TGF-b is a multifunctional cytokine upregulated in the gastric mucosa of H. pylori-infected individuals, which plays a key role in wound healing, differentiation, proliferation and regulation of immunological events in the gastrointestinal mucosa. 25, 26 Expression of TGF-b1 has been shown to be influenced by polymorphisms localized in the TGFB1 gene. Specifically, the TGFB1 T þ 869C (Leu-Pro) and the TGFB1 G þ 915C (Arg-Pro) polymorphisms, localized in the signal peptide sequence of the TGF-b1 precursor, may affect the stability and the activation process of TGF-b1, leading to altered concentrations of TGF-b1. 27 Several case-control studies evaluating the involvement of these TGFB1 polymorphisms in susceptibility to chronic inflammatory diseases and different types of cancers have been reported. 22, 23, 28, 29 However, to our knowledge, this study is the first to analyse the role of the TGFB1 T þ 869C and the TGFB1 G þ 915C polymorphisms in susceptibility to PU and GC. Recently, a study from China showed that the TGFB1 C-509T gene polymorphism was not associated with the development of premalignant gastric lesions (gastric intestinal metaplasia) in individuals infected with H. pylori. 30 In our study, no differences in carriage, genotype and allele frequencies of the TGFB1 T þ 869C and the TGFB1 G þ 915C polymorphisms between GC patients and controls were found. The lack of association with other several clinical characteristics such as age of onset, smoking habit, H. pylori status, localization and histological type of the tumour, suggests that these gene polymorphisms do not constitute a genetic risk factor for the predisposition to GC. However, this finding does not exclude a key role for this cytokine in GC susceptibility, progression and metastasis. 15, 16 In fact, the relevance of TGF-b1 on gastric carcinogenesis has been shown in a recent study by Wang et al. 31 in which blockade of TGF-b or TGF-b signalling pathway has been suggested as potential therapy to prevent GC cells from invading and metastasizing.
On the other hand, a different distribution of the TGFB1 T þ 869C genotypes was observed when patient groups were compared. Thus, individuals homozygous for the TGFB1 þ 869*C allele (Pro/Pro) were significantly more prevalent in the group of patients with non-cardia GC than in the group with DU. DU and non-cardia GC are two different entities associated to infection with H. pylori that have completely opposite pathogenesis; the former is related to a predominant antral gastritis and high acid secretion, whereas non-cardia GC is associated with more severe corpus gastritis and low acid secretion. 32, 33 Among a wide variety of functions, homeostasis of gastric acidity has been also documented to be partially regulated by TGF-b1. Thus, TGF-b1 type I and type II receptors are clearly expressed in chief and parietal cells of the gastric fundic glands. 34 Several experimental studies have demonstrated that TGF-b inhibits pentagastrin-stimulated gastric acid secretion in rats, suggesting a new mechanism of TGF-b action in gastroduodenal ulcer healing. 35 On the contrary, inhibition of gastric acid secretion results in increased gastric pH, low levels of ascorbic acid, 36 a diminished ability to block the endogenous formation of N-nitroso compounds 37 and a higher risk of GC. Based on these data, the different distribution of TGFB1 þ 869 genotypes between DU and GC patients observed in our study, besides supporting the concept of a different genetic background for both entities, might help explain, at least in part, how H. pylori can induce such divergent outcomes, in this case by regulating homeostasis of gastric acid secretion.
It has been shown that the presumed role of TGF-b1 in gastrointestinal ulcer healing is through its stimulating effects on the regeneration of epithelial cells and connective tissues, and the promotion of angiogenesis. [38] [39] [40] Blockade of intestinal epithelial TGF-b activity by dominant-negative TGF-b type II receptor impaired intestinal wound healing in vitro and in vivo studies. 41 In addition, exogenous administration of TGF-b not only increased the healing of DU rate but also reversed the negative effects induced by indomethacin on the ulcer healing process. 14 We report in this study the association between the carriage of TGFB1 þ 869C/C genotype and reduced risk of developing DU. Interestingly, no association between the TGFB1 þ 869 gene polymorphism and GU was observed. A potential explanation for these results could be provided by the fact that carriage of the TGFB1 þ 869C/C genotype has been related with high production of TGF-b1, 19, 42, 43 which through its capacity to stimulate cellular proliferation and differentiation and its acid inhibitory effects on the stomach might decrease the risk of developing DU disease. Unfortunately, the approach used in this study was not informative in correlating TGFB1 polymorphisms and variations in TGF-b1 production, so further studies will be needed in order to clarify the real functional significance of this finding.
Most of the patients included in our study were infected with H. pylori (96% in DU, 84% in GU and 75% in GC), which is consistent with previous results reported in the literature showing a strong association between H. pylori infection, GC and PU. 9, 44 The CagA/ VacA status within PU patients, GC patients and controls was not linked to the genotype distribution or allele frequency of TGFB1 gene polymorphisms. These results are in line with previous studies showing no association between several cytokine gene polymorphisms and infection with H. pylori CagA/VacA strains. 45 As suggested by Figueiredo et al., 45 this finding indicates that there is no preferential colonization of specific hosts (defined by TGFB1 gene polymorphisms) by specific bacterial strains. Cytokines form a highly complex interacting network, which includes cascades of gene activation and suppression. Besides TGFB1, other pro-and anti-inflammatory cytokine genes involved in the inflammatory response to H. pylori infection might play an important role in the pathogenesis of GC and PU. In this regard, we have previously reported the association between the simultaneous carriage of IL-1B þ 3954*T and IL-1RN*2 alleles and reduced risk of developing DU. 46 In addition, haplotype TNFA-I, which encompasses the TNFA-308 G and TNFA-238 G alleles, was identified as a risk factor for both, GU and DUs in patients with H. pylori infection. 47 On the other hand, we have also analysed the influence of IL-1B and TNFA gene polymorphisms in the susceptibility to GC disease in a Spanish population with high H. pylori infection rate. Although preliminary, our results show no involvement of IL-1B-511, IL-1B þ 3954, IL-1RN and TNFA-308 gene polymorphisms in the development of non-cardia GC. 48 These findings are in contrast with those previously reported in several European populations. [49] [50] [51] However, recent studies performed in other Caucasian populations also did not confirm the role of cytokine gene polymorphisms in gastric carcinogenesis. [52] [53] [54] The reasons for these discrepant results are unclear and differences in sample size, methodologies, ethnicities and dominance of different aetiologic factors in different populations have been suggested as possible explanations.
In summary, our results suggest that the TGFB1 T þ 869C gene polymorphism is involved in the susceptibility to DU. They also support the concept of a different genetic background for the development of DU and noncardia GC. A better understanding of how H. pylori can induce such divergent diseases may lead to novel treatments or methods for prevention of these conditions. Further studies at different geographic areas and ethnic groups are warranted in order to elucidate the real contribution of host genetic factors in the susceptibility to H. pylori-related diseases.
Patients and methods
Study population
This case-control study included 142 unrelated Spanish Caucasian patients with GC, and 200 patients with PU attending the Hospital Clinico in Zaragoza, Spain. A total of 342 sex-and age-matched (75 years) community unrelated healthy volunteers with no symptoms of gastrointestinal disease served as controls. All subjects gave informed consent for participation in the study, which was conducted in accordance with the Ethical Committee of the Hospital. The diagnosis of GU or DU was established on the basis of conventional clinical and endoscopic findings. All GC patients were identified by endoscopic and pathological diagnosis at the hospital from February 2002 to November 2005. GC patients were included in the study if they could be interviewed and provide biological samples of adequate quality for genetic analysis. Of the total 142 GC patients, 32 (22.5%) were classified as cardia or gastroesophageal junction cancers and 110 (77.5%) as non-cardia or distal GC cases. According to Lauren's criteria, 55 56, 57 NSAIDs use The use of NSAIDs at the time of the diagnosis of PU was determined by structured data collection. A patient was considered positive if the drug had been taken within the week before the hospital admission of the endoscopic diagnosis of DU or GU. , Arg-Pro) (refSNP ID: rs1800471) in the first exon of the TGFB1 gene was amplified according to previously described methods. 21 A volume of 10 ml of each polymerase chain reaction (PCR) product was digested with 2 U of MspA1I (10 U/ml, NEB, Izasa, Barcelona, Spain), 2 ml 10 Â buffer 1, 0.15 ml bovine serum albumin (100 Â ) and 7.65 ml H 2 O for 5 h at 371C. Digests were then electrophoresed on a 3% metaphor agarose gel, which resulted in four fragments of 85, 67, 40 and 15 bp (allele T) or in five fragments of 73, 67, 40, 15 and 12 bp (allele C), respectively. For typing the codon 25 polymorphism at position þ 915 (G-C), 10 ml of the PCR products were digested with 2 U of Sau96I (Roche) for 5 h at 371C. Allele C was defined by the presence of two fragments of 113 and 94 bp and allele G by the presence of an intact fragment of 207 bp.
Statistical analysis
Comparison of the genotype and allele frequencies in patients and healthy controls was performed using the w 2 test with Yates' correction or Fisher's exact test, if needed. The magnitude of the association of the TGFB1 gene polymorphisms in each group was estimated by the OR and 95% CI. A two-sided P-value o0.05 was considered statistically significant. Hardy-Weinberg equilibrium was tested in the control samples by a w 2 test with 1 d.f. Estimated haplotype frequencies and linkage disequilibrium coefficients for the TGFB1 þ 869 and TGFB1 þ 915 loci in patients and controls were calculated using the Estimating Haplotype frequencies software program (available from ftp://linkage.rockefeller.edu/software/eh). In addition, unconditional logistic regression analysis was carried out to quantify the influence of both genetic and environmental factors for PU and GC as dependent variables. Categorical variables included in the models were codified as dummy variables. The statistical analyses were undertaken using SPSS 13.0 for Windows (SPSS Ibérica, Madrid, Spain).
Based on previous studies, we estimated that a 10% difference in the carrier status of the different TGFB1 T þ 869C and TGFB1 G þ 915C genotypes could be present in patients. Based on this assumption, we calculated that it was necessary to study 130 subjects in each group in order to have 0.80 power and a a-value of 0.05.
